198 related articles for article (PubMed ID: 20207506)
21. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
[TBL] [Abstract][Full Text] [Related]
22. Favorable Preliminary Outcomes for Men With Low- and Intermediate-risk Prostate Cancer Treated With 19-Gy Single-fraction High-dose-rate Brachytherapy.
Krauss DJ; Ye H; Martinez AA; Mitchell B; Sebastian E; Limbacher A; Gustafson GS
Int J Radiat Oncol Biol Phys; 2017 Jan; 97(1):98-106. PubMed ID: 27979460
[TBL] [Abstract][Full Text] [Related]
23. ASCENDE-RT: An Analysis of Treatment-Related Morbidity for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost with a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.
Rodda S; Tyldesley S; Morris WJ; Keyes M; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):286-295. PubMed ID: 28433432
[TBL] [Abstract][Full Text] [Related]
24. Late toxicity after intensity-modulated radiation therapy for localized prostate cancer: an exploration of dose-volume histogram parameters to limit genitourinary and gastrointestinal toxicity.
Pederson AW; Fricano J; Correa D; Pelizzari CA; Liauw SL
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):235-41. PubMed ID: 21163587
[TBL] [Abstract][Full Text] [Related]
25. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial.
Stromberg J; Martinez A; Gonzalez J; Edmundson G; Ohanian N; Vicini F; Hollander J; Gustafson G; Spencer W; Yan Di
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):161-71. PubMed ID: 7543891
[TBL] [Abstract][Full Text] [Related]
26. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study.
Martin T; Baltas D; Kurek R; Röddiger S; Kontova M; Anagnostopoulos G; Dannenberg T; Buhleier T; Skazikis G; Tunn U; Zamboglou N
Strahlenther Onkol; 2004 Apr; 180(4):225-32. PubMed ID: 15057433
[TBL] [Abstract][Full Text] [Related]
27. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
28. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.
Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486
[TBL] [Abstract][Full Text] [Related]
29. High-dose-rate brachytherapy with two or three fractions as monotherapy in the treatment of locally advanced prostate cancer.
Hoskin P; Rojas A; Ostler P; Hughes R; Alonzi R; Lowe G; Bryant L
Radiother Oncol; 2014 Jul; 112(1):63-7. PubMed ID: 25018002
[TBL] [Abstract][Full Text] [Related]
30. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: a feasibility report.
Martinez AA; Pataki I; Edmundson G; Sebastian E; Brabbins D; Gustafson G
Int J Radiat Oncol Biol Phys; 2001 Jan; 49(1):61-9. PubMed ID: 11163498
[TBL] [Abstract][Full Text] [Related]
31. Development of late toxicity and International Prostate Symptom Score resolution after external-beam radiotherapy combined with pulsed dose rate brachytherapy for prostate cancer.
Pieters BR; Rezaie E; Geijsen ED; Koedooder K; van der Grient JN; Blank LE; de Reijke TM; Koning CC
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):758-64. PubMed ID: 20800377
[TBL] [Abstract][Full Text] [Related]
32. Multi-institutional Phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities.
Nihei K; Ogino T; Onozawa M; Murayama S; Fuji H; Murakami M; Hishikawa Y
Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):390-6. PubMed ID: 20832180
[TBL] [Abstract][Full Text] [Related]
33. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes and toxicity in patients treated with brachytherapy for prostate adenocarcinoma younger than 60 years of age at treatment with minimum 10 years of follow-up.
Buckstein M; Carpenter TJ; Stone NN; Stock RG
Urology; 2013 Feb; 81(2):364-8. PubMed ID: 23374803
[TBL] [Abstract][Full Text] [Related]
35. Late toxicity and five year outcomes after high-dose-rate brachytherapy as a monotherapy for localized prostate cancer.
Ghadjar P; Oesch SL; Rentsch CA; Isaak B; Cihoric N; Manser P; Thalmann GN; Aebersold DM
Radiat Oncol; 2014 May; 9():122. PubMed ID: 24885327
[TBL] [Abstract][Full Text] [Related]
36. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
Makino T; Mizokami A; Namiki M
Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
[TBL] [Abstract][Full Text] [Related]
38. Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: Comparison of two consecutive high-dose-rate schemes.
Olarte A; Cambeiro M; Moreno-Jiménez M; Arbea L; Pérez-Gracia JL; Gil-Bazo I; Pascual I; Aristu J; Martínez-Monge R
Brachytherapy; 2016; 15(2):127-35. PubMed ID: 26832677
[TBL] [Abstract][Full Text] [Related]
39. Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05).
Lawton CA; Hunt D; Lee WR; Gomella L; Grignon D; Gillin M; Morton G; Pisansky TM; Sandler H
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):1-7. PubMed ID: 21470793
[TBL] [Abstract][Full Text] [Related]
40. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]